Michael Fort, executive chairman at Concept Life Sciences, said: “We are excited to add Aquila to the Concept group.

“Aquila and Concept have been built around the same value of working closely with customers to tailor services according to the project objectives, and together we will provide high quality, integrated solutions.”

Professor Jonathan Seckl, vice principal of planning, resources and research policy at Edinburgh university, said: “We congratulate the Aquila team on this milestone in their approach to building advanced biology into innovative drug discovery.

“This investment highlights the University’s commitment to successfully translating our world-class research into practical application by industry.”

  • Edinburgh BioQuarter is adding a commercial facility to help meet demand for space at the health and science campus.

Work has begun on a two-storey 1,200 sqm modular building, which will provide a mix of specialist office and lab space. The building will open in early 2018 and is situated in the south of Edinburgh BioQuarter – adjacent to Nine and the Centre for Dementia Prevention. 

The development follows on from the success of Nine, Edinburgh BioQuarter’s first commercial building, which is now fully occupied. Nine is home to more than 20 life sciences businesses.

Edinburgh BioQuarter: demand outstripping supply at Nine


Derek McCrindle, Head of Business Infrastructure at Scottish Enterprise, said: “Edinburgh BioQuarter is one of the most significant long-term programmes Scottish Enterprise has undertaken to accelerate growth in the Life Sciences sector.

“Demand has outstripped supply at Nine, demonstrating the pull of the location as a base for Life Science businesses.”

The start of these works brings the value of construction projects currently taking place at Edinburgh BioQuarter to more than £200m.

Construction began earlier this month on the University’s £50m Centre for Tissue Repair. The new Centre will increase the number of stem cell scientists based at Edinburgh BioQuarter, making it one of the largest concentrations in the world.

NHS Lothian’s £150m Royal Hospital for Children and Young People and Department of Clinical Neurosciences is due to open in 2018.

  • Scottish Equity Partners has made a “significant” investment in London-based Dotmatics, a global scientific informatics software company.

Dotmatics provides solutions for pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. The funding will enable Dotmatics to continue its investment into product innovation and customer success, as well as to strengthen operations in each of its key geographies.    

The investment deal was led by SEP partners Keith Davidson and Jan Rutherford.